Managing Expectations for Libido Medications

It is dosed at bedtime to help decrease the risk of adverse events occurring

The overlooked science of women’s desire

Cindy views the advocacy work she’s done with Addyi as part of a larger health care revolution. “Women are now like, ‘I’m gonna demand the care I deserve,’” she says. “The female population is challenging the medical establishment. Medicine’s following their lead, not the other way around.” At the front of that invigorated pack? Cindy, their pink-suited entrepreneurial leader, who’ll never stop talking about a woman’s right to understand that better sex and true desire are part of her overall wellness.

Liver impairment

Lindsay Geller is the lifestyle director at Women’s Health, where she oversees the Sex & Love, Relationships, and Life sections and manages Women’s Health+ content. She has 10 years of experience covering sex, relationships, health, fitness, and general lifestyle topics for print and digital publications. She currently lives in New Jersey with her husband and loves going on runs around her local park with her rescue dog. WASHINGTON (WLS) -- The Food and Drug Administration has approved the first prescription drug to boost sexual desire in women, nicknamed the "little pink pill." The daily pill, called flibanserin or Addyi, claims to treat low libido in women by working with chemicals in the brain to treat Hypoactive Sexual Desire Disorder, HSDD, which affects approximately one in 10 women. Sprout Pharmaceuticals, maker of the pill, says it will become available on Oct. due to possible hypotension, syncope and central nervous system depression (such as sleepiness and sedation).

Patients should discontinue treatment after eight weeks if they do not report an improvement in sexual desire and associated distress.” Chaudhari says, “Looking at the

mechanism of the drug is really interesting because we don’t totally understand how sexual response works in women.” That’s because sexual response in women is multifactorial.

• The term "pink pill" is often used metaphorically for gender-specific health solutions.
• Ongoing research aims to develop more effective, safe female libido enhancers.
• Cultural acceptance of such pills varies globally, affecting accessibility.
• Awareness about female sexual health continues to grow, driving demand.

“Women are affected by chemical levels in the brain, and we think when we have high levels of one

What does this approval mean for other women’s health products?

17 and will cost between $30 and $75 a month with insurance, on par with Viagra. The FDA's approval comes with heavy safety restrictions which will likely prevent Addyi from achieving the blockbuster sales of male impotence drugs like Viagra, which have generated billions of dollars. The new drug's label will carry a bold warning that combining it with alcohol can cause dangerously low blood pressure and fainting. Those problems can also occur if the drug is taken alongside certain common medications, including drugs used to treat yeast infections. The FDA has denied approval for the drug twice since 2010, citing concerns with effectiveness vigora spray and safety.

Does Addyi interact with other medicines (drug interactions)?

In June 2015, an FDA advisory panel voted in favor of the drug after hearing emotional testimony. The Associated Press contributed to this report. In the headlines it's often called female Viagra, but medical experts say it should not at all be compared to the erectile dysfunction drug. The female version will become available in October and carries the brand name, Addyi. In June, it became the first Food and Drug Administration-approved drug to treat what's clinically called hypoactive sexual desire disorder in women. chemical, perhaps we can have a decrease in sexual desire versus other chemicals that might improve sexual desire,” she said.

• Some pink pills combine herbal extracts like ginseng or maca for effects.
• They are popular in wellness circles for enhancing intimacy and confidence.
• Research on pink pills' long-term safety is limited; caution is advised.
• Available through online stores, pharmacies, or clinics in some regions.

In addition, external factors such as mood and relationship issues can affect a woman’s sexual desire.

Side Effects

But the pink-tinted pill was resoundingly rejected twice before by the FDA and Addyi continues to have more than its share of detractors. While the drug maker, Sprout Pharmaceuticals, says clinical trials showed it to improve women's libido, critics say the pill carries too many potential risks and questions still abound over whether female sexual dysfunction can be treated with medication. Joining Chicago Tonight to discuss the pill are Dr. Stacy Tessler Lindau, associate professor of obstetrics/gynecology and medicine-geriatrics at the University of Chicago Medical School; Dr. Jessica Shepherd, University of Illinois College of Medicine at Chicago; Alessandra Hirsch, a project consultant with PharmedOut, a Georgetown University Medical Center project; and Carl Jenkins, an FDA regulatory lawyer at the Wood Burditt Group. “This is why it makes it so difficult; research around this topic is so limited,” she said.

• Pink pills are part of a broader trend towards female-centered wellness.
• They can potentially enhance intimacy, confidence, and overall satisfaction.
• Unregulated products pose risks of contamination or inappropriate ingredients.
• Always verify product credentials and manufacturer reputation before purchase.

“Studies on women are more difficult because we don’t totally understand women’s sexual response.” “Viagra is just used for men with erectile dysfunction, and it supposed to be used immediately before intercourse to maintain an erection,” Chaudhari said.

The Big Pink Fight for the Little Pink Pill

Now, when she wears pink, she feels as if she’s “suiting up to go on mission.” That mission? “It’s you getting to live your life on your own terms with complete agency over your pleasure,” Cindy says. That proud pink stance wasn’t her natural inclination. Like many women, Cindy had “absolutely no sex education” growing up, she says. Her father worked for the State Department, and she moved so much that she was in a different school every year from fourth grade through high school.

Is Lack of Desire all in Our Heads??

“No chance I was getting clear messaging on sex,” she says, other than the societal narrative that “pleasure is a man’s to receive and a woman’s to deliver.” She sees firsthand the lasting effects of this notion. Whenever she meets someone new—say, at a cocktail party—and they ask what she does, she watches their reaction carefully as she explains her work with Addyi. “If it’s a male-female couple, the woman kind of shuts down, like, ‘Oh yeah, okay, I don’t need that,’ and the man leans forward and goes, ‘Can I take it?’” she says. “You see societal conditioning in a snapshot: The woman’s like, ‘I’m not supposed to talk about this,’ and the man’s like, ‘I am entitled to this.’” That might explain why, although Addyi received FDA approval and came on the market in 2015, you haven’t heard much about it. “It tells you how deeply embedded this is culturally—the daring to talk about women’s sexual pleasure.” Addyi was immediately dubbed “the female Viagra,” and for better or worse (mostly for worse, per Cindy), the moniker stuck. “[Addyi] is meant to be a maintenance medication for women.

See also:

Addyi is the brand name of flibanserin, which was approved earlier this month by the FDA to “treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women,” according to an FDA press release. “It’s basically decreased interest in sexual activity or desire, which is a very common problem for premenopausal and postmenopausal women,” Dr. Angela Chaudhari, a Northwestern Medicine gynecologist explained. “I think it affects 40 percent of premenopausal women and 60 percent of postmenopausal women. Unfortunately, it’s a big problem in the country and it’s not frequently addressed.” “Addyi is a serotonin 1A receptor agonist and a serotonin 2A receptor antagonist, but the mechanism by which the drug improves sexual desire and related distress is not known. “It’s not something you can pop before intercourse and be in the mood to have intercourse,” she added.

Proper Use

“In a way, you think [the comparison] is amazing: This can be as transformative for women’s health as Viagra was for men’s. But it also sets up the wrong notion of how desire works for women,” Cindy says. “Sex, for women, is not the performative act. It’s about being in the headspace of feeling sexy, being interested, responding to your partner or to [other] cues. We’re brain flow, not blood flow.” The comparison to Viagra also epitomizes the double standard that Cindy has spent a decade trying to dismantle.

What should I tell my healthcare provider before using Addyi?

“The atrocity of women’s health is that we’re not taken seriously, and it shows up in so many ways,” she says. “First, it shows up in the regulatory queue, where there’s a double standard to get to an approval.” Viagra was “deemed to meet such an important unmet medical need” that the FDA fast-tracked the review process and approved it in less than six months. Despite having “three times as many patients’ worth of data” proving the efficacy of Addyi, Cindy says, it spent six years in the regulatory queue waiting for approval. That double standard also shows up in advertising guidelines: Hypoactive sexual desire disorder contains the word sex (the horror! “When we first put up ads, they were all taken down,” Cindy says. “You have to take it every day in a long-term format.” Liz Canner is the director

When a drug became a movement

Even now, you’ll find Addyi commercials mostly on podcasts with a female-leaning audience, not on national TV, in clear contrast to the onslaught of ads for mail-order generic Viagra. Last but lovegra women certainly not least, the double standard shows up in the medical establishment. Perimenopausal women are the largest demographic using Addyi—a patient group that has been, until recently, largely ignored, undermined, and misdiagnosed. (Right now, Addyi is FDA-approved only to treat premenopausal women, but Cindy just received word that it’s been “fast-tracked” for approval in postmenopausal women in the U.S., which is a promising sign.) Whether officially diagnosed with HSDD or not, women in perimenopause tend to face the same struggles: mood imbalances, libido shifts, weight gain, and sleep disturbances. “Addyi works on every single one of those things,” Cindy says, adding that it does so without hormones.

Learn to recognize the signs of HSDD in your patients.4

For women who can’t use vaginal estrogen or hormone replacement therapy for other medical reasons, Addyi can be a boon, but the comparison to Viagra has “almost allowed the medical community to not understand how Addyi works,” she says. “Sometimes I’ll sit in a room with physicians and say, ‘Tell me how it works.’ They don’t know that it’s brain chemistry.” To be clear, progress has been made. Today, you can’t pass a board exam to be an ob-gyn or urologist without answering a question about Addyi. Still, Cindy dreams of the day when doctors ask about sexual satisfaction as a routine part of a woman’s annual checkup. The longer-term goal is changing what the medical establishment prioritizes, from the top down. of Orgasm Inc., a documentary about the pharmaceutical industry’s race to create a female version of Viagra.

• The pink pill targets issues like low desire and menstrual discomfort.
• It may improve mood and increase energy levels in women.
• Side effects can include headaches, nausea, or hormonal imbalances.
• Its use is often personalized based on hormonal levels and health status.